Drugs / Tregalizumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04673591 | Dec 2020 → Jan 2022 | allergic asthma, house allergic alveolitis | T-Balance Therapeutics GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01999192 | Oct 2013 → Jul 2015 | rheumatoid arthritis | Biotest | Terminated | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tregalizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04673591 ↗ |
| Action | Inhibit | “Biological activity was shown by dose-dependent CD4 downmodulation.” PMID 29343509 ↗ Jan 2018 |
| Modality | Monoclonal antibody | “humanized anti-CD4 mAb” NCT01999192 ↗ |
| Route | Subcutaneous | “25mg Tregalizumab s.c. weekly” NCT01999192 ↗ |
| Target | CD4 | “Biological activity was shown by dose-dependent CD4 downmodulation.” PMID 29343509 ↗ Jan 2018 |